Published in final edited form as:

Metabolism. 2011 December ; 60(12): 1757–1766. doi:10.1016/j.metabol.2011.04.009.

Nebivolol Improves Insulin Sensitivity in the TGR(Ren2)27 Rat

Camila Manrique^{1,*}, Guido Lastra^{1,*}, Javad Habibi^{1,3,*}, Lakshmi Pulakat¹, Rebecca Schneider^{1,3}, William Durante², Roger Tilmon¹, Jenna Rehmer¹, Melvin R Hayden¹, Carlos M. Ferrario⁴, Adam Whaley-Connell^{1,3}, and James R. Sowers^{1,2,3}

¹Diabetes Cardiovascular Center of Excellence, University of Missouri-Columbia School of Medicine

²Medical Pharmacology and Physiology, University of Missouri-Columbia School of Medicine

³Research Service, Harry S. Truman Veterans Affairs Medical Center, Columbia, Missouri, 65201

⁴Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, North Carolina, 27157

Abstract

Objective—Hypertension is often associated with increased oxidative stress and systemic insulin resistance. Use of β adrenergic receptor blockers in hypertension is limited due to potential negative influence on insulin sensitivity and glucose homeostasis. We sought to determine the impact of nebivolol, a selective vasodilatory β_1 adrenergic blocker, on whole-body insulin sensitivity, skeletal muscle oxidative stress, insulin signaling and glucose transport in the transgenic TG(mRen2)27rat (Ren2). This rodent model manifests increased tissue renin angiotensin expression, excess oxidative stress, and whole-body insulin resistance.

Research design and methods—Young (age 6-9 wks) Ren2 and age-matched Sprague-Dawley control rats were treated with nebivolol 10 mg/kg/day or placebo for 21 days. Basal

© 2011 Elsevier Inc. All rights reserved.

Corresponding Author: James R. Sowers, MD University of Missouri-Columbia School of Medicine D109 HSC Diabetes Center One Hospital Drive Columbia, MO 65212 T (573)882-2273 F (573)884-5530 sowersj@health.missouri.edu.

*Authors contributed equally to this paper.

Author contributions: Camila Manrique, Javad Habibi and Guido Lastra: These are the leading authors, who actively and equally participated in the design, planning and conduction of the study, as well as in the data collection and analysis. These authors also actively lead the writing and edition of the manuscript.

Lakshmi Pulakat: This author was actively involved in the analysis and interpretation of the data, as well as in the planning of the manuscript.

Rebecca Schneider: As laboratory manager, this author was the leader in the collection of data in all the animals and tissues used in this paper.

William Durante: Dr. Durante participated in the collection and analysis of data pertaining to oxidative stress in our tissues.

Roger Tilmon: This author actively participated in the production of immunohistochemistry data.

Jenna Rehmer: This author participated in the acquisition of western blot data used to evaluate insulin signaling in our skeletal muscle samples.

Melvin R Hayden: This author was actively involved and led the collection of transmission electron microscopy data, as well as its analysis, in our samples.

Carlos M. Ferrario: Dr. Ferrario kindly provided the Ren2 rats used in our experiments.

Adam Whaley-Connell: Dr. Whaley-Connell provided daily mentorship in completion of the studies, assistance in the development of our manuscript, and financial support through CDA funds with the Dept. of Veteran's Affairs.

James R. Sowers: Dr. Sowers is the senior author and was the leader in the planning, conduction of the study, as well as in analysis of the data and in the writing and correction of the manuscript. Our study was made possible by Dr. Sowers's funding obtained through the National Institutes of Health and Forest Laboratories.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Disclosures: Drs. Pulakat, Manrique and Sowers have research funding from Forest Laboratories

measurements were obtained for glucose and insulin to calculate the Homeostasis Model Assessment (HOMA-IR). Additionally, insulin metabolic signaling, NADPH oxidase activity, reactive oxygen species (ROS), and ultrastructural changes as evaluated by transmission electron microscopy were examined ex vivo in skeletal muscle tissue.

Results—The Ren2 rat demonstrated systemic insulin resistance as examined by HOMA-IR, along with impaired insulin metabolic signaling in skeletal muscle. This was associated with increased oxidative stress and mitochondrial remodeling. Treatment with nebivolol was associated with improvement in insulin resistance and decreased NADPH oxidase activity/levels ROS in skeletal muscle tissue.

Conclusions—Nebivolol treatment for 3 weeks reduces NADPH oxidase activity and improves systemic insulin resistance, in concert with reduced oxidative stress in skeletal muscle in a young rodent model of hypertension, insulin resistance and enhanced tissue RAS expression.

Keywords

Insulin resistance; oxidative stress; skeletal muscle

Introduction

Hypertension frequently coexists with insulin resistance and type 2 diabetes mellitus: it is estimated that approximately 50% of hypertensive patients have evidence of insulin resistance [1,2]. In several population-based studies elevated serum insulin levels predict higher blood pressures and future development of hypertension [1,3,4,5]. Insulin resistance that is associated with hypertension is characterized by impaired insulin metabolic signaling that results in reduction of glucose transport and decreased non-oxidative glucose metabolism in insulin-sensitive tissues such as skeletal muscle [2,3].

Activation of the renin-angiotensin-aldosterone system (RAAS) leads to increased generation of reactive oxygen species (ROS) in several tissues [3]. The consequent increase in oxidative stress, in turn, contributes to a decrease in insulin metabolic signaling in various insulin responsive tissues [3]. In skeletal muscle and cardiovascular tissue, the enzymatic complex NADPH oxidase is critical in mediating RAAS generation of ROS and impaired insulin metabolic signaling [1,3,6,7,8,9,10]. ROS also diminishes the bioavailability of nitric oxide (NO) through conversion of locally released NO to peroxynitrite (ONOO⁻) [3]. This reduction in bioavailable NO contributes to micro-vascular dysfunction that results in decreased delivery of insulin and glucose to skeletal muscle tissue and other insulin-sensitive tissues, resulting in decreased insulin-mediated glucose transport [2,11,12,13]. The resulting decrease in insulin metabolic signaling is characterized by impaired insulin receptor substrate 1 (IRS-1) engagement with the p85 regulatory component of phosphoinositide 3-kinase (PI3K) and protein kinase B (Akt) phosphorylation/activation [2]. Thus, strategies to reduce oxidative stress and increase bioavailable NO have considerable potential utility in treating hypertension in conditions characterized by insulin resistance [4,2].

Therapeutic strategies that inhibit the RAAS, as well as attenuation of oxidant stress, have been shown to improve insulin sensitivity in hypertensive rodents [6,14,15,16]. On the other hand, classic beta adrenergic receptor blockers have been shown to aggravate insulin resistance in hypertensive individuals [4, 17]. In the context of treatment of hypertension in insulin resistant individuals, nebivolol a selective β_1 -adrenergic blocker with vasodilatory and anti-oxidant properties, has been shown to improve oxidant stress and systemic insulin sensitivity; likely through reductions in NADPH oxidase activity and enhancement of endothelial NO synthase activity [18,19,20]. Thereby, we hypothesized that in vivo

treatment with nebivolol in a rodent model of RAAS overactivation would improve systemic insulin sensitivity and insulin-stimulated glucose utilization through reductions in NADPH oxidase-dependent oxidant stress. To address this hypothesis we employed the transgenic TG(mRen2)27 (Ren2) rat model which manifests increased tissue renin and angiotensin (Ang II) expression, hypertension and systemic insulin resistance [6,15,16].

Materials and Methods

Animals and treatments

All animal procedures were approved by the University of Missouri animal care and use committees and housed in accordance with NIH guidelines. Male Transgenic TG(mRen2)27 (Ren2) rats (6-9 weeks of age) and age-matched Sprague-Dawley (SD) littermates were randomly assigned to placebo (Ren2-C and SD-C), or nebivolol treatment (Ren2-N and SD-N, between 5-13 animals per group) paradigms. Ren2-N and SD-N rats received 10 mg/kg/day of nebivolol released via an implanted osmotic mini-pump for 21 days. The statistical power was calculated to detect statistically significant differences in our primary outcome, which was systemic insulin sensitivity as evaluated by HOMA-IR.

Systolic Blood Pressure (SBP) and Total Body Weight

Restraint conditioning was initiated before blood pressure measurements. SBP was measured in triplicate, on separate occasions throughout the day, using the tail-cuff method (Harvard Systems, Student Oscillometric Recorder) [15,16] prior to initiation of treatment and at the end of the treatment period prior to sacrifice at 21 days. Total body weights were assessed on the day of sacrifice.

Insulin sensitivity assessment

HOMA-IR—Prior to sacrifice, serum samples were obtained for fasting insulin and glucose measurements. Homeostasis model assessment (HOMA)-IR was calculated as (fasting insulin (μ U/ml) $\times$ fasting glucose [mg/dl])/405 [22].

NADPH oxidase activity

NADPH oxidase activity was determined in plasma membrane fractions as described [16,20]. Aliquots of red gastrocnemius muscle membrane and cytosolic fractions were incubated with NADPH (100mM) at 37°C. NADPH oxidase activity was determined by measuring the conversion of Radical Detector (Cayman Chemical) in the absence and presence of NADPH inhibitor diphenyleneiodonium sulfate (500 μ M) using spectrophotometric (450nm) techniques.

NADPH oxidase subunit immunostaining

Harvested soleus muscle tissue was prepared as previously described [15]. Briefly, sections were incubated with 1:100 dilution goat p47^{phox}, Nox2 (Santa Cruz), and 1:200 of mouse anti Rac1 antibodies in 10 fold diluted blocking agent (primary antibodies) overnight at room temperature. After washing, sections were incubated with 1:300 Alexa-fluor donkey anti-goat 647 (Invitrogen), p47, Nox2 and donkey anti-mouse for Rac1 for 4 hours. The slides, mounted with mowiol, were examined under a bi-photon confocal microscope and the images were captured with LSM imaging system and the signal intensities were analyzed and quantified with MetaVue.

Oxidative Stress

ROS tissue levels—Using isolated red gastrocnemius muscle sections levels of ROS were measured by the lucigeninchemiluminescence technique [20]. Sections were

homogenized in sucrose buffer using a glass/glass homogenizer. Homogenates were centrifuged: $1,500 \text{ rcf} \times 10 \text{ min}$ at 4°C . Supernatants (whole homogenate) were removed and placed on ice. Whole homogenate ($100 \mu\text{l}$) was added to 1.4 ml of 50 mM phosphate (KH_2PO_4) buffer. After dark adaptation for 1 h , samples were counted every 30 s for 10 min on a scintillation counter, and the last 5 min of counts were averaged. Samples were then normalized to total protein in the whole homogenate and to day to day control. Values are expressed as counts per minute per milligram of protein (cpm/mg).

3-Nitrotyrosine(3-NT) immunostaining—3-NT was quantified as previously described [20]. Samples were incubated with 1:20 primary rabbit polyclonal anti-nitrotyrosine antibody overnight. Sections were then washed and incubated with secondary antibodies, biotinylated linked, and labeled with Streptavidin for 30 min each. After several rinses with TBST, diaminobenzidine was applied for 10 min , sections were rinsed several times with distilled water and stained with hematoxylin for 150 sec , dehydrated in an ethanol series, and mounted with a permanent mounting media. The slides were checked under a bright field microscope and the $40\times$ images captured with a cool snap cf camera and intensities measured with MetaView.

Immunological Analysis of IRS-1, PI3K, and IRS-1/PI3K association

Four μm soleus cross sections ($n=6$ for all groups) were incubated overnight with rabbit anti-IRS-1 1:100, (Santa Cruz Biotechnology), 1:50 (phosphatidylinositol 3-kinase binding site) (BD Transduction, Inc., Lake Placid, NY) [20]. After washing several times, the sections were incubated with Alex flour donkey anti rabbit 647 for IRS-1 and mounted with mowiol. Under a bi-photon confocal microscope images were captured with LSM imaging system and signal intensities were analyzed with MetaVue.

Dual Immunological Staining of IRS-1 and PI3K

After blocking of non-specific sites, the sections were incubated with 1:50 dilution rabbit IRS-1 (Santa Cruz), for overnight at room temperature. The following day, the section were washed with HEPES buffer ($3\times 15 \text{ mins}$) and incubated with 1:50 of mouse anti PI3K (BD Transduction) in 10 fold diluted blocking agent overnight at room temperature. After washing, sections were incubated with 1:300 mixed Alexa-fluor donkey anti-rabbit and donkey anti mouse 647 (Invitrogen) for 4 hours and mounted with mowiol. The slides were examined under a bi-photon confocal microscope, and the images were captured with LSM imaging system and the signal intensities were analyzed and quantified with MetaVue.

Co-immunoprecipitation and Western Blot analysis for IRS-1 and ubiquitin

To immunoprecipitate IRS-1, red gastrocnemius tissue was powdered under liquid nitrogen and was lysed in lysis buffer and the cell debris was removed by quick centrifugation at 3000 rpm for 5 minutes . The lysates ($800 \mu\text{g}$ protein) were initially incubated with $10 \mu\text{L}$ of agarose protein G plus for 30 min on ice, subjected to centrifugation at 3000 rpm for 3 minutes , and the supernatant was incubated with $20 \mu\text{l}$ of agarose-conjugated mouse anti-IRS-1 antibody (Santa Cruz Biotech, Inc.) for 5 hrs at 4°C . The immunoprecipitated material was collected by centrifugation 3000 rpm for 3 min , washed three times with phosphate-buffered saline and resuspended in $40 \mu\text{l}$ of $2\times\text{SDS}$ -loading buffer. Proteins were separated by SDS-polyacrylamide gel electrophoresis, transferred to nitrocellulose membrane and probed with rabbit anti-IRS1 antibody or rabbit anti-ubiquitin antibody (Cell Signaling Technology Inc.). Immunoblotting experiments were also performed using whole tissue lysates ($50 \mu\text{g}$ protein).

Transmission Electron Microscopy

Sections of soleus muscle were thinly sliced and placed immediately in primary fixative (2% glutaraldehyde, 2% paraformaldehyde in 0.1 M Na cacodylate buffer, pH 7.35). A laboratory microwave oven was utilized for secondary fixation with acetone dehydration and Epon-Spurr resin infiltration. Specimens were placed on a rocker overnight at room temperature, embedded the following morning, and polymerized at 60°C for 24 hours. A microtome (Ultracut UCT, Leica) with a 45° diamond knife (Diatome) was used to prepare thin (85-nm) sections. Later, the specimens were stained with 5% uranyl acetate and Sato's triple-lead stain and examined with a transmission electron microscope [15,20].

Mitochondrial quantification

The same sample size (1/3 of each soleus muscle) was used in all of the experimental procedures. Animals (n=5) were harvested and tissues were analyzed by light microscopy. Four microns paraffin processed sections of soleus muscle strips of each treatment group (SD-C, SD-N, Ren2-C and Ren2-N) were de-paraffinized, rehydrated and stained with complex IV subunit 1. Our soleus tissue sections were incubated with mouse anti-human complex IV subunit 1 antibody (Mitosciences, Eugene, OR) 3 µg/ml in 10 fold diluted blocker. After washing with HEPES wash buffer, the sections were incubated with 1:300 donkey anti-mouse Alexa fluor 647 (Invitrogen, Eugene, OR). After four hours, the sections were washed and incubated with 1:2000 DAPI. After 10 minutes, slides were washed, mounted with mowiol, and evaluated with a multiphoton confocal system. From each section, three 63× confocal images (1040×1040 Pixel) were captured by a Bi-photon confocal microscope from different areas of the sections randomly. Images were captured by LSM imaging system, enhanced with Photoshop, and mitochondria were quantified by MetaMorph. The images were enhanced by Photoshop and the relative number, the signal intensities and the areas of the signals in each image were quantified by Metamorph.

Statistics

All results are presented as means ± standard error. Two way analysis of variance (ANOVA) with Fisher's Least Significant Differences (LSD) and unpaired t test was performed as appropriate.

Results

SBP and TBW

As previously published [21], at initiation and end of the treatment intervention period, SBP was higher in Ren2-C group when compared with SD-C. Treatment with nebivolol resulted in a significant SBP reduction in the Ren2 compared to the non-treated animals as previously reported [21]. Nebivolol treatment for 21 days was not associated with a significant weight reduction in the Ren2 animals.

Indices of Insulin Sensitivity

In this investigation we utilized HOMA-IR to evaluate whole-body insulin sensitivity [22]. HOMA-IR was significantly decreased in the Ren2-C compared to SD (2.79 ± 0.5 vs 1.16 ± 0.3 , $p < 0.05$) (Figure 1A). Treatment with nebivolol improved whole-body insulin sensitivity in Ren2-N (1.87 ± 0.61 vs 2.79 ± 0.52 , $p < 0.05$) compared to untreated Ren2 rats.

Total IRS-1, IRS-1 and IRS-1/PI3-K association

Insulin metabolic signaling is dependent on IRS-1 engagement of the p85 regulatory component of PI3-K [2,23,24]. To determine whether proteosomal degradation contributes to decreased IRS-1 and subsequent reductions in insulin metabolic signaling and

downstream PI3-K, we examined total IRS-1 levels by immunoblotting and by immunoprecipitation of ubiquitin. Both methods demonstrated a reduction in total IRS-1 content in the Ren2 compared to SD controls which paralleled increased co-precipitation of IRS-1 with ubiquitin in the Ren2-C (Figure 1B). Nebivolol treatment increased IRS-1 levels and reduced the co-precipitation of ubiquitin with IRS-1 in Ren2 animal skeletal muscle. To further characterize the protein-protein interaction between IRS-1 and PI3-K, we co-localized both in soleus muscle by immunohistochemistry. However, total IRS-1 and PI3-K was not significantly changed between groups based on signal intensities (Figure 1C).

Oxidative Stress

To ascertain the effects of in vivo treatment with nebivolol on ex vivo skeletal muscle oxidative stress in the Ren2, we measured total ROS levels and 3-NT content as a marker for ONOO⁻ formation. ONOO⁻ is a highly reactive oxidant species that can be formed endogenously by the interaction of NO and superoxide anion, and this product reacts readily with tyrosine residues of proteins to form 3-NT [3,13]. ROS levels were higher in placebo-treated Ren2 controls (1.22 ± 0.11 RLU/s/mg) compared with the SD group (1.0 ± 0.03 RLU/s/mg, $p=0.003$). Treatment with nebivolol reduced ROS levels in Ren2-N rats skeletal muscle (0.96 ± 0.04 RLU/s/mg, $p=0.02$) (Figure 2A). Furthermore, 3-NT immunostaining was increased in Ren2-C when compared with SD controls (26.8 ± 1.88 vs. 1.53 ± 0.51 average gray-scale intensities, $p<0.05$). Nebivolol reduced 3-NT immunostaining in Ren2 tissues (26.8 ± 1.88 vs. 2.7 ± 0.83 average gray-scale intensity, $p<0.05$) (Figure 2B).

NADPH oxidase activity

NADPH oxidase is a primary mediator of RAAS-mediated generation of superoxide anions (4). NADPH oxidase activity was elevated in skeletal muscle of Ren2 when compared to SD (18.6 ± 1.1 vs. 1.62 ± 1.1 mOD/min/mg, $p<0.05$), and decreased in the nebivolol-treated Ren2 rats (14.9 ± 1.1 mOD/min/mg, $p<0.05$) (Figure 3A). Analysis of NADPH oxidase subunits by immunohistochemistry demonstrated parallel findings, with a significant increased Rac1, and p47 subunits in Ren2 animals compared to controls (Figure 3B). Treatment with nebivolol for 3 weeks significantly decreased the level of p47, and Rac1 in soleus muscle samples relative to Ren2 control animals (Figure 3B).

Mitochondrial density

Complex IV was measured as an indicator of total mitochondrial content [15,20,21]. This is a large transmembrane protein complex that accepts electrons from cytochrome c (e.g. cytochrome c oxidase). Subunit 1 is the largest of the cytochrome C complex and is primarily responsible for heme-copper oxygenase and dioxygen-proton pumping. Immunohistochemistry for complex IV subunit 1 demonstrated increases in Ren2 compared to SD controls ($p<0.05$), and significantly improved with nebivolol treatment. As a marker for content, the Complex IV subunit 1 was consistent with transmission electron microscopy analysis, which is suggestive of increased mitochondrial density with disorganized morphology in subsarcolemmal, intermyofibrillar, and perinuclear regions of the myocyte within the Ren2 (Figure 4). These ultrastructural abnormalities in Ren-2 skeletal muscle tissue were largely attenuated with nebivolol treatment (Figure 4).

Discussion

In this investigation, we examined the impact of nebivolol treatment on systemic insulin sensitivity, skeletal muscle oxidative stress, insulin metabolic signaling, and glucose uptake in a rodent model of tissue RAAS activation. Our results are commensurate with previous reports that Ren2 rats manifest impaired whole body insulin sensitivity, enhanced skeletal muscle NADPH oxidase activity, increased ROS levels and diminished skeletal muscle

insulin signaling [6,15,16]. Data from the current investigation suggest that treatment of young insulin resistant Ren2 rats for 3 weeks with nebivolol improves systemic insulin resistance in concert with reductions of NADPH oxidase generation of oxidative stress in skeletal muscle tissue.

Work in our laboratory with the Ren2 rat model over the last several years and support that young (6-9 weeks old) animals exhibit both systemic and skeletal muscle insulin resistance without having extensive cardiovascular and kidney disease, as do older animals. Our observation that nebivolol treatment improved insulin sensitivity in transgenic RAAS mediated insulin resistant rats complement prior observations in Ang II treated [23] and overweight rodents [20], as well as insulin resistant hypertensive persons [8,18,19,25,26]. Indeed, previous studies have demonstrated that nebivolol reduces oxidative stress and increases tissue bioavailable NO levels in cardiovascular and renal tissue [7,17,23,27]. Reduced tissue bioavailable NO levels appears to be an important factor involved in Ang II-mediated elevation of blood pressure and decreased delivery of insulin and uptake of glucose by the skeletal muscle, processes critical for skeletal muscle utilization of glucose [1,6,14,15,16,28]. In the context of increased tissue NADPH oxidase activity and elevated ROS levels, NO is converted to ONOO⁻, reducing bioavailable NO levels in cardiovascular, renal and skeletal muscle tissue [11,29].

Data generated in this investigation suggest that a treatment strategy targeting reductions in ROS in the transgenic Ren2 rat results in improved insulin metabolic signaling in soleus muscle. ROS generation in skeletal muscle tissue in this model is dependent on RAAS-mediated generation of the superoxide anion (O₂⁻) through NADPH oxidase activation [15,16], as well as through mitochondrial generation of ROS [21]. Effects of nebivolol treatment on NADPH oxidase activity in skeletal muscle tissue included reductions in Rac1 activation, as well as decreased levels of the subunit p47. These subunits changes accompanied reduced NADPH oxidase activity and reduced tissue levels of 3-NT. ONOO⁻, a highly reactive oxidant species, is formed endogenously by the interaction of NO and O₂⁻, and this product reacts readily with tyrosine residues of proteins and lipoproteins to form 3-NT [9,13]. This process contributes to a reduction in bioavailable NO and also indirectly to eNOS uncoupling, thereby further reducing bioavailable NO.

Consistent with previous reports [6,15,16], we found increased oxidative stress in skeletal muscle in the Ren2 model, a change that occurs in parallel with diminished co-localization of IRS-1 and PI3-K. Indeed, increased ROS levels in skeletal muscle occur contemporaneous with reductions in IRS-1, as well as increases in association of ubiquitin with IRS-1. Increased proteosomal degradation of IRS-1 in Ren2 skeletal muscle tissue occurs, in part, due to increased activation of redox sensitive serine kinases, and their promotes serine phosphorylation and ubiquitination (and hence proteosomal degradation) of IRS-1 [3]. Our results also suggest that increases in ONOO⁻ (measured as 3-NT), contribute to degradation of IRS-1 and impairment in insulin metabolic signalling, findings largely improved by nebivolol.

Interestingly, our data unexpectedly suggest an effect of nebivolol in healthy (SD) control rats treated with nebivolol, regarding HOMA-IR and IRS-1. The underlying reasons are unclear, but these changes might reflect a differential response to the use of nebivolol in normotensive, normoglycemic and healthy animals, as opposed to its effects on Ren2 animals, which are insulin resistant and exhibit inappropriately high oxidative stress in several tissues including skeletal muscle.

Components of the electron transfer chain are heme-containing proteins encoded by the mitochondrial genome, complex IV or cytochrome c oxidase being the most prominent [30].

In this regard, subunits I-III of cytochrome c oxidase are critical determinants of O₂ uptake and O₂⁻ anion formation [31]. This notion is consistent with our observation of increases in complex IV, subunit 1 (a marker of total mitochondrial content) as well as ultrastructural evidence of increased mitochondria contemporaneous with increased ROS in Ren2 skeletal muscle tissue. In this context, reductions in complex IV levels, NADPH oxidase activity and ROS levels following nebivolol treatment may be driving the decrease in HO-1 expression in Ren2 skeletal muscle tissue.

Similar to previous studies, several ultrastructural abnormalities were observed by transmission electron microscopy in Ren2 skeletal muscle tissue, including increased number and structural abnormalities of mitochondria [15,16]. In contrast to previous reports of decreased skeletal muscle mitochondrial levels in sedentary obese and diabetic animals and humans, the current study involved a physically active and non-obese rodent model, which might explain the finding of increased mitochondria biogenesis. The increased Ren2 skeletal muscle mitochondrial biogenesis and mitochondria structural abnormalities were largely corrected by in vivo nebivolol treatment for 3 weeks. Increased mitochondrial citrate synthase and the electron transport chain activity likely also contributed to the increased levels of ROS and 3-NT in Ren2 skeletal muscle tissue. Accordingly, nebivolol may reduce oxidative stress in skeletal muscle tissue by reducing both NADPH oxidase and mitochondrial generation of ROS [21]. These reductions in oxidative stress occur in concert with improvements in insulin metabolic signaling. These results are consistent with the notion that anti-hypertensive treatment strategies that reduce skeletal muscle oxidative stress may correct help correct impaired insulin sensitivity in hypertension. In humans, earlier clinical trials validated the agent as an effective anti-hypertensive both when used as monotherapy and in combination with other agents. Recent trials have reported that nebivolol is an effective anti-hypertensive with beneficial, or at least neutral, effects on lipids and carbohydrate metabolism [8].

In conclusion, the present investigation demonstrates that 3 weeks treatment with nebivolol, a selective vasodilatory β 1 adrenergic receptor blocker, improves insulin resistance, reduces NADPH oxidase activity and increases bioavailable NO in a transgenic rodent model with increased skeletal muscle oxidative stress due to enhanced activation of the RAAS. Since insulin resistance is implicated in the pathophysiology of hypertension, our findings showing improvements of insulin sensitivity with nebivolol deserve further investigation. It will be important to carry longer term studies that examine the impact of nebivolol on insulin sensitivity and glucose metabolism in models of increased tissue RAS expression.

Precis

Use of betablockers in hypertension is controversial due to an adverse impact on insulin sensitivity. Treatment of Ren2 rats with nebivolol improves insulin sensitivity with a parallel decreased in oxidative stress.

Acknowledgments

The authors wish to acknowledge the Electron Microscope Core Facility of the University of Missouri for tissue preparation.

Funding: This research was supported by NIH R01 HL73101-01A1 (J.R.S.) and HL-51952 (C.M.F.), and HL59976 (W.D.), Veterans Affairs Merit System 0018 (J.R.S.), Career Development Award-2 (A.W.C.), UM Research Board (A.W.C.) and the Forest Research Institute.

Abbreviations

HOMA-IR	Homeostasis Model Assessment
ROS	Reactive oxygen species
NADPH oxidase	Nicotinamide adenine dinucleotide phosphate-oxidase
RAAS	Renin-angiotensin-aldosterone system
NO	Nitric oxide
IRS-1	Insulin receptor substrate 1
PI3K	Phosphoinositol 3-kinase
Akt	Protein kinase B
Ang II	Angiotensin II
Ren2	Transgenic TG(mRen2)27
SD	Sprague-Dawley
SBP	Systolic Blood Pressure
3-NT	3-Nitrotyrosine
ONOO⁻	Peroxynitrite

REFERENCES

1. Ferrannini E, Natali A, Capaldo B, et al. Insulin resistance, hyperinsulinemia and blood pressure: role of age and obesity. European Group for the Study of Insulin Resistance (EGIR). Hypertension. 1997; 30:1144–49. [PubMed: 9369268]
2. Whaley-Connell A, Sowers JR. Hypertension and insulin resistance. Hypertension. 2009; 54:462–64. [PubMed: 19635987]
3. Cooper SA, Whaley-Connell A, Habibi J, et al. Role of renin-angiotensin-aldosterone system-induced oxidative stress in cardiovascular insulin resistance. Am J Physiol Heart Circ Physiol. 2007; 293:H2009–H2023.
4. Manrique C, Johnson M, Sowers JR. Thiazide diuretics alone or with beta-blockers impair glucose metabolism in hypertensive patients with abdominal obesity. Hypertension. 2010; 55:15–17. [PubMed: 19917873]
5. Raitakari OT, Porkka KV, Rönnekaa T, et al. The role of insulin in clustering of serum lipids and blood pressure in children and adolescents. Diabetologia. 1995; 38:1042–50. [PubMed: 8591817]
6. Blendea MC, Jacobs D, Stump CS, et al. Abrogation of oxidative stress improves insulin sensitivity in the Ren-2 rat model of tissue angiotensin II overexpression. Am J PhysiolEndocrinolMetab. 2005; 288:E353–E359.
7. Dessy C, Saliez J, Ghisdal P, et al. Endothelial beta 3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol. Circulation. 2005; 112:1198–1205. [PubMed: 16116070]
8. Fogari R, Zoppi A, Lazzari P, et al. Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes. J Hum Hypertens. 1997; 11:753–57. [PubMed: 9416986]
9. Garrido AM, Griendling KK. NADPH oxidases and angiotensin II receptor signaling. Mol Cell Endocrinol. 2009; 302:148–58. [PubMed: 19059306]
10. Robertson RP, Harmon J, Tran PO, et al. Glucose toxicity in (2)-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes. 2003; 52:581–87. [PubMed: 12606496]

11. Frisbee JC, Samora JB, Basile DP. Angiostatin does not contribute to skeletal muscle microvascular rarefaction with low nitric oxide bioavailability. *Microcirculation*. 2007; 14:145–53. [PubMed: 17365669]
12. Frisbee JC, Samora JB, Peterson J, et al. Exercise training blunts microvascular rarefaction in the metabolic syndrome. *Am J Physiol Heart CircPhysiol*. 2006; 291:H2483–92.
13. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. *Physiol Rev*. 2007; 87:315–424. [PubMed: 17237348]
14. Cole BK, Keller SR, Wu R, et al. Valsartan protects pancreatic islets and adipose tissue from the inflammatory and metabolic consequences of a high-fat diet in mice. *Hypertension*. 2010; 55:715–21. [PubMed: 20100990]
15. Lastra G, Habibi J, Whaley-Connell AT, et al. Direct renin inhibition improves systemic insulin resistance and skeletal muscle glucose transport in a transgenic rodent model of tissue renin overexpression. *Endocrinology*. 2009; 150:2561–8. [PubMed: 19246535]
16. Lastra G, Whaley-Connell A, Manrique C, et al. Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG(mRen2)27 rat. *Am J PhysiolEndocrinolMetab*. 2008; 295:E110–6.
17. Mason RP, Kubant R, Jacob RF, et al. Loss of arterial and renal nitric oxide bioavailability in hypertensive rats with diabetes: effect of beta-blockers. *Am J Hypertens*. 2009; 22:1160–6. [PubMed: 19730416]
18. Celik T, Iyisoy A, Kursaklioglu H, et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. *J Hypertens*. 2006; 24:591–6. [PubMed: 16467663]
19. Poirier L, Cleroux J, Nadeau A, et al. Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients. *J Hypertens*. 2001; 19:1429–35. [PubMed: 11518851]
20. Zhou X, Ma L, Habibi J, et al. Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the Zucker obese rat. *Hypertension*. 2010; 55:880–8. [PubMed: 20176997]
21. Whaley-Connell A, Habibi J, et al. Nebivolol reduces proteinuria and renal NADPH oxidase-generated reactive oxygen species in the transgenic Ren2 rat. *Am J Nephrol*. 2009; 30:354–60. [PubMed: 19609077]
22. Muniyappa R, Lee S, Chen H, et al. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. *Am J PhysiolEndocrinolMetab*. 2008; 294:E15–26.
23. Oelze M, Daiber A, Brandes RP, et al. Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats. *Hypertension*. 2006; 48:677–84. [PubMed: 16940222]
24. Manrique C, Lastra G, Gardner M, et al. The renin angiotensin aldosterone system in hypertension: roles of insulin resistance and oxidative stress. *Med Clin North Am*. 2009; 93:569–82. [PubMed: 19427492]
25. Pischon T, Sharma AM, Mansmann U, et al. Effect of forced titration of nebivolol on response rate in obese hypertensive patients. *Am J Hypertens*. 2003; 16:98–100. [PubMed: 12517695]
26. Rizo E, Bairaktari E, Kostoula A, et al. The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study. *J CardiovascPharmacolTher*. 2003; 8:127–34.
27. Mollnau H, Schulz E, Daiber A, et al. Nebivolol prevents vascular NOS III uncoupling in experimental hyperlipidemia and inhibits NADPH oxidase activity in inflammatory cells. *ArteriosclerThrombVascBiol*. 2003; 23:615–21.
28. Lee-Young RS, Ayala JE, Hunley CF, et al. Endothelial nitric oxide synthase is central to skeletal muscle metabolic regulation and enzymatic signaling during exercise in vivo. *Am J Physiol Regul Integr Comp Physiol*. 2010; 298(5):R1399–408. [PubMed: 20200137]
29. Lesniewski LA, Donato AJ, Behnke BJ, et al. Decreased NO signaling leads to enhanced vasoconstrictor responsiveness in skeletal muscle arterioles of the ZDF rat prior to overt diabetes and hypertension. *Am J Physiol Heart CircPhysiol*. 2008; 294:H1840–50.

30. Richter OM, Ludwig B. Cytochrome c oxidase—structure, function, and physiology of a redox-driven molecular machine. *Rev PhysiolBiochemPharmacol.* 2003; 147:47–74.
31. Kim JA, Wei Y, Sowers JR. Role of mitochondrial dysfunction in insulin resistance. *Circ Res.* 2008; 102:410–14.

Figure 1. Nebivolol improves systemic insulin resistance and insulin metabolic signaling in the Ren2 rat

Panel A. HOMA-IR was calculated as $[\text{basal insulin (mU/mL)} \times \text{basal serum glucose (mg/dL)}] / 405$ after treatment with nebivolol or placebo for 3 weeks. Sprague-Dawley control (SD-C, n=4), Sprague-Dawley treated with nebivolol (SD-N, n=6), Ren2 control (Ren2-C, n=5), and Ren2 treated with nebivolol (Ren2-N, n=4). **Panel B** depicts a representative image of co-immunoprecipitation and western blot analysis for IRS-1 and IRS-1 ubiquitin association. **Panel C** displays representative fluorescent images of total IRS-1, PI3K and IRS-1/PI3K association and corresponding measures of intensity. Sprague-Dawley control (SD-C; n=5), Sprague-Dawley treated with nebivolol (SD-N; n=5), Ren2 control (Ren2-C; n=5), and Ren2 treated with nebivolol (Ren2-N; n=5). Values are expressed as means $\pm$ SE. Scale bar, 50 μm . * $p < 0.05$ compared with SD-C. # $p < 0.05$ compared with Ren2-C

Figure 2. Nebivolol improves Oxidant Stress in Ren2 skeletal muscle

Panel A. ROS formation as determined by chemiluminescence. Sprague-Dawley control (SD-C; n=7), Sprague-Dawley treated with nebivolol (SD-N; n=9), Ren2 control (Ren2-C; n=7), and Ren2 treated with nebivolol (Ren2-N; n=13). Values are presented as means $\pm$ SE. *p = 0.02 compared with SD-C. # p = 0.03 compared with Ren2-C. **Panel B.** Measures of 3-nitrotyrosine by immunostaining and corresponding measures of intensity. Sprague-Dawley control (SD-C; n=5), Sprague-Dawley treated with nebivolol (SD-N; n=5), Ren2 control (Ren2-C; n=5), and Ren2 treated with nebivolol (Ren2-N; n=5). Values are expressed as means $\pm$ SE. *p < 0.05 compared with SD-C. # p < 0.05 compared with Ren2-C. . Scale bar = 50 μ m.

Figure 3. Nebivolol decreases NADPH oxidase activity and subunit expression in Ren2 skeletal muscle

Panel A. Total NADPH oxidase enzyme activity analyzed in red gastrocnemius by spectrophotometry. **Panel B.** NADPH oxidase subunits examined using immunohistochemistry. Representative images and corresponding measurements of intensity are presented. Sprague-Dawley control (SD-C; n=5 for NADPH oxidase activity and NADPH oxidase subunits), Sprague-Dawley treated with nebivolol (SD-N; n = 6 for NADPH oxidase activity, n=5 for NADPH oxidase subunits), Ren2 control (Ren2-C; n=4 for NADPH oxidase, n=5 for NADPH oxidase subunits), and Ren2 treated with nebivolol (Ren2-N; n=9 for NADPH oxidase, n=5 for NADPH oxidase subunits). Values are presented as means $\pm$ SE. *p< 0.01 compared with SD-C. # p< 0.05 compared with Ren2-C. Scale bar = 50 μ m.

Figure 4. Nebivolol reduces mitochondrial density in Ren2 skeletal muscle

Panel A. Immunohistochemistry for mitochondrial quantification (complex IV subunit 1).

Values presented as means $\pm$ SE. *, $p < 0.05$ compared with SD-C; #, $p < 0.05$ when nebivolol-treated Ren2 (Ren2-N) are compared with Ren2 controls (Ren2-C). Scale bar, 50 μ m. **Panel B.** Representative ultrastructural examination of soleus skeletal muscle utilizing transmission electron microscopy (TEM) demonstrating increased mitochondrial number in the subsarcolemmal, intermyofibrillar, pericapillary, and perinuclear regions of the myocyte with disorganized morphology in the Ren2-C compared with SD-C. Abnormalities in Ren-2 were largely attenuated with nebivolol treatment. Arrows signal mentioned findings.

Magnification, $\times 2500$. Scale bar, 0.5 μ m.